

Form 605

Corporations Act 2001
Section 671B

Notice of ceasing to be a substantial holder

To Company Name/Scheme Mayne Pharma Group Limited

ACN/ARSN ACN 115 832 963

1. Details of substantial holder (1)

Name Mithra Pharmaceuticals SA, Estetra SRL and their associates listed in Annexure A

ACN/ARSN (if applicable) N/A

The holder ceased to be a substantial holder
on

21 June 2023

The previous notice was given to the
company on

14 May 2021

The previous notice was dated

14 May 2021

2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's votes affected
21/6/2023	Mithra Pharmaceuticals SA, Estetra SRL and their associates listed in Annexure A	On-market sale	\$16,296,206	4,221,815 fully paid ordinary shares	4,221,815 fully paid ordinary shares

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Refer to Annexure A	The associates listed in Annexure A are members of the same group of companies as Mithra Pharmaceuticals SA and Estetra SRL.

4. Addresses


The addresses of persons named in this form are as follows:

Name	Address
Estetra SRL	Rue Saint-Georges 5, 4000 Liège, Belgium
Mithra Pharmaceuticals SA	Rue Saint-Georges 5, 4000 Liège, Belgium
Associates listed in Annexure A	Refer to Annexure A

Signature

print name CHRISTOPHE MARÉCHAL capacity Chief Financial Officer

sign here




date 22 June 2023

Directions

1. If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
2. See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
3. See the definition of "associate" in section 9 of the Corporations Act 2001.
4. Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
5. Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
6. The voting shares of the company constitute one class unless divided into separate classes.
7. Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

Annexure A

This is Annexure A referred to in Form 605 (Notice of ceasing to be a substantial holder), signed by me and dated 22 June 2023.

Signature: 

Name: CHRISTOPHE MARÉCHAL

Date: 22 June 2023

Title: Chief Financial Officer

Associates

The following is a list of associates of Mithra Pharmaceuticals SA and Estetra SRL.

Name of Associate	Address
Mithra Recherche et Développement SA	Rue Saint-Georges 5, 4000 Liège, Belgium
Neuralis SA	Rue Saint-Georges 5, 4000 Liège, Belgium
Mithra Lëtzebuerg SA	Boulevard de la Petrusse 124, 2330 Luxembourg
Mithra Pharmaceuticals CDMO SA	Rue Saint-Georges 5, 4000 Liège, Belgium
Mithra Pharmaceuticals GmbH	Promenade 3-9 Raum 22 DE - 52076 Aachen, Germany
WeCare Pharmaceuticals BV	Lagedijk 1-3, NL - 1541 KA Koog aan de Zaan
Novalon SA	Rue Saint-Georges 5, 4000 Liège, Belgium
Donesta Bioscience BV	Boslaan 11 3701 CH Zeist, The Netherlands